212 related articles for article (PubMed ID: 12690969)
1. [Amphotericin B and its lipid formulations].
Ritter J
Mycoses; 2002; 45 Suppl 3():34-8. PubMed ID: 12690969
[TBL] [Abstract][Full Text] [Related]
2. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
3. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
4. Treatment of fungal infections with ABLC in the home-care setting.
Weissmann AC
J Assoc Nurses AIDS Care; 1999; 10(3):43-52. PubMed ID: 10707695
[TBL] [Abstract][Full Text] [Related]
5. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
6. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
7. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
9. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
10. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
Maniwa T; Yamamoto Y
Nihon Yakurigaku Zasshi; 2007 Feb; 129(2):129-34. PubMed ID: 17299241
[No Abstract] [Full Text] [Related]
11. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
[TBL] [Abstract][Full Text] [Related]
12. [New lipid formulations of amphotericin B. Review of the literature].
Andrès E; Tiphine M; Letscher-Bru V; Herbrecht R
Rev Med Interne; 2001 Feb; 22(2):141-50. PubMed ID: 11234672
[TBL] [Abstract][Full Text] [Related]
13. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
14. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
15. Lipid complexes of amphotericin B: the competitive picture.
Richardson MD
J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817
[No Abstract] [Full Text] [Related]
16. ABELCET treatment.
Boyle JA; Swenson CE
J Clin Pharmacol; 1999 Apr; 39(4):427-8. PubMed ID: 10197303
[No Abstract] [Full Text] [Related]
17. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry.
Pappas PG
Clin Infect Dis; 2005 May; 40 Suppl 6():S379-83. PubMed ID: 15809923
[No Abstract] [Full Text] [Related]
20. Lipid-based antifungal agents.
Arikan S
Cell Mol Biol Lett; 2002; 7(2):220-1. PubMed ID: 12097922
[No Abstract] [Full Text] [Related]
[Next] [New Search]